Coronavirus Update: Moderna Snags Vaccine EUA
Plus: NIAID Test Antibodies In Hospitalized Patients, Asia Developments
The FDA granted emergency authorization for Moderna's mRNA-1273 following a 17 December advisory committee vote in its favor. There have also been more supply deals and approvals in Asia.
You may also be interested in...
Private Company Edition: The astonishing pace of venture capital investment in drug development continues with another $1.5bn in financings of $100m or more, including $152m for Pyxis and $126m for Omega. New VC funds also continue to launch, including RiverVest’s fifth fund, totaling $275m.
The dispute over a likely 60% reduction in supplies of AstraZeneca's COVID-19 vaccine shows no sign of resolution. Meanwhile, Lilly, Vir/GSK team up on COVID-19 antibody combination and Moderna negotiates sale of 100 million additional vaccine doses to US.
Regeneron's antibody cocktail prevented deaths and mechanical ventilation in hospitalized patients on low-flow oxygen. Also, Pfizer and BioNTech will supply an additional 100m doses of the companies' COVID-19 vaccine to the US government for $1.95bn, while Merck & Co signed a contract for its COVID-19 treatment MK-7110.